High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial
Jeroen van Dorp, Christodoulos Pipinikas, Britt B.M. Suelmann, Niven Mehra, Nick van Dijk, Giovanni Marsico, Maurits L. van Montfoort, Sophie Hackinger, Linde M. Braaf, Tauanne Amarante, Charlaine van Steenis, Kirsten McLay, Antonios Daletzakis, Daan van den Broek, Maaike W. van de Kamp, Kees Hendricksen, Jeantine M. de Feijter, Thierry N. Boellaard, Richard P. Meijer, Antoine G. van der Heijden, Nitzan Rosenfeld, Bas W.G. van Rhijn, Greg Jones, Michiel S. van der Heijden
Topics & Concepts
IpilimumabNivolumabMedicineCohortInternal medicineHazard ratioOncologyBladder cancerUrologyCancerConfidence intervalImmunotherapyBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersUrinary and Genital Oncology Studies